JP2024545183A5 - - Google Patents
Info
- Publication number
- JP2024545183A5 JP2024545183A5 JP2024534647A JP2024534647A JP2024545183A5 JP 2024545183 A5 JP2024545183 A5 JP 2024545183A5 JP 2024534647 A JP2024534647 A JP 2024534647A JP 2024534647 A JP2024534647 A JP 2024534647A JP 2024545183 A5 JP2024545183 A5 JP 2024545183A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- raav
- particles
- expression construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288520P | 2021-12-10 | 2021-12-10 | |
| US63/288,520 | 2021-12-10 | ||
| PCT/US2022/081323 WO2023108159A1 (en) | 2021-12-10 | 2022-12-09 | Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545183A JP2024545183A (ja) | 2024-12-05 |
| JP2024545183A5 true JP2024545183A5 (enExample) | 2025-12-17 |
Family
ID=86731334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534647A Pending JP2024545183A (ja) | 2021-12-10 | 2022-12-09 | ウイルスベクターによりｂａｇ－３関連心筋症を処置するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250041453A1 (enExample) |
| EP (1) | EP4444364A4 (enExample) |
| JP (1) | JP2024545183A (enExample) |
| KR (1) | KR20240118855A (enExample) |
| AU (1) | AU2022407655A1 (enExample) |
| CA (1) | CA3242351A1 (enExample) |
| IL (1) | IL313427A (enExample) |
| WO (1) | WO2023108159A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250195694A1 (en) * | 2022-03-18 | 2025-06-19 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector |
| KR20250169529A (ko) * | 2023-02-13 | 2025-12-03 | 아스트라제네카 아일랜드 리미티드 | 유전자 요법을 위한 Bcl2-관련 아타노진 3(BAG3)을 인코딩하는 핵산 |
| WO2024215655A1 (en) * | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Cardioprotective bag3 therapies |
| AU2024265705A1 (en) * | 2023-05-02 | 2025-11-20 | Research Institute At Nationwide Children's Hospital | Gene therapy for treatment of protein misfolding diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015117010A2 (en) * | 2014-01-31 | 2015-08-06 | Temple University Of The Commonwealth System Of Higher Education | Bag3 as a target for therapy of heart failure |
| WO2015153889A2 (en) * | 2014-04-02 | 2015-10-08 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| US20190328836A1 (en) * | 2017-01-09 | 2019-10-31 | Duke University | Methods for treating ischemic injury |
| CN113015742A (zh) * | 2018-06-08 | 2021-06-22 | 联邦高等教育系统天普大学 | 优化bag3基因治疗 |
| KR20210112339A (ko) * | 2019-01-04 | 2021-09-14 | 울트라제닉스 파마수티컬 인코포레이티드 | 윌슨병을 치료하기 위한 유전자 요법 구축물 |
| WO2021154923A2 (en) * | 2020-01-29 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
-
2022
- 2022-12-09 AU AU2022407655A patent/AU2022407655A1/en active Pending
- 2022-12-09 US US18/717,532 patent/US20250041453A1/en active Pending
- 2022-12-09 KR KR1020247023092A patent/KR20240118855A/ko active Pending
- 2022-12-09 JP JP2024534647A patent/JP2024545183A/ja active Pending
- 2022-12-09 WO PCT/US2022/081323 patent/WO2023108159A1/en not_active Ceased
- 2022-12-09 CA CA3242351A patent/CA3242351A1/en active Pending
- 2022-12-09 EP EP22905439.0A patent/EP4444364A4/en active Pending
- 2022-12-09 IL IL313427A patent/IL313427A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220331409A1 (en) | Factor ix gene therapy | |
| JP2022500066A5 (enExample) | ||
| JP2026027271A5 (enExample) | ||
| JP2024545186A5 (enExample) | ||
| JP2021531752A5 (enExample) | ||
| JP6573991B2 (ja) | 血管性浮腫の治療としてのｃ１ｅｉのアデノ随伴ウイルス介在性送達 | |
| JP2023524291A5 (enExample) | ||
| JP2024523707A5 (enExample) | ||
| JP2025515979A5 (enExample) | ||
| JP2020518268A5 (enExample) | ||
| JP2022530824A5 (enExample) | ||
| JP2024513907A5 (enExample) | ||
| JP2021500922A5 (enExample) | ||
| JP2025509828A5 (enExample) | ||
| JP2019524090A5 (enExample) | ||
| JP2023503850A5 (enExample) | ||
| JP2024546103A5 (enExample) | ||
| JP2025512574A5 (enExample) | ||
| JP2020510433A5 (enExample) | ||
| US11517631B2 (en) | Factor IX encoding nucleotides | |
| JP2024500786A5 (enExample) | ||
| US12415850B2 (en) | Compositions and methods for regulating production of an antibody like protein and ribonucleic acid | |
| EP3773744B1 (en) | Compositions and methods for the treatment of dominantly-inherited catecholaminergic polymorphic ventricular tachycardia | |
| JP2022514271A5 (enExample) | ||
| JP2025503868A5 (enExample) |